• Oriva Therapeutics is launched with the support of Asabys, focused on developing innovative therapies in women’s health• The company incorporates two advanced assets from Oncostellae and Medibiofarma,...

Navarra, Spain – August 28, 2025 — Medibiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Novel Agonists of the PPAR-γ Receptor for the...

Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Continue their Support for the Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy...

Palobiofarma and Medibiofarma open new headquarters in the AINbuilding in Cordovilla, Spain · The new facilities, of 200 square meters, consist of an office area next to a fully equipped medicinal...

Navarra – February 2025 – Medibiofarma S.L., a clinical-stage biotechnology company developinga portfolio of new small molecule therapies announced the award of the European CommissionSeal of Excellence...

Navarra – February 2024 – Medibiofarma S.L., a clinical-stage biotechnology company developing a portfolio of new therapies for the treatment of neurodegenerative diseases and other pathologies announced...

Navarra – May 10, 2023 – Medibiofarma S.L., a clinical-stage biotechnology company developing aportfolio of new therapies for the treatment of gastrointestinal (GI) diseases as well as othercancer and...

Crohn’s & Colitis Foundation’s IBD Ventures Awards Investment to Support Development of Medibiofarma’s Novel First-In-Class PPARg Partial Agonist Oral Therapy (MBF-118) for Treatment...